Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Organic compounds

A product, the technology of staurosporine, applied in the direction of organic chemistry, can solve problems such as differences

Inactive Publication Date: 2010-03-10
NOVARTIS AG
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, we also know that different crystal forms of the same drug may have substantial differences in some important properties of the drug

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Organic compounds
  • Organic compounds
  • Organic compounds

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0092] Example 1 Purification of Staurosporine B1 to Staurosporine B2 Using Methanesulfonic Acid and Triethylamine

[0093] Add staurosporine B1 and ethanol into the reactor. The suspension was heated to about 70°C. Methanesulfonic acid was added to the suspension, and the resulting solution was aged. Activated charcoal and Hyflo are added and the mixture is aged. Filter the suspension, and wash the filter device and filter cake with ethanol several times. The clear filtered solution was transferred to another reactor and cooled to 60 °C. Triethylamine diluted with ethanol was slowly added to the reaction mixture. Afterwards, the suspension was cooled to about 20°C and aged. Staurosporine B2 was separated by filtration. The product was washed several times with ethanol.

Embodiment 2

[0094] Example 2 Purification of Crude Staurosporine B1 to Staurosporine B2 by Crystallization

[0095] Add staurosporine B1 and benzyl alcohol into the reactor. The suspension was heated to about 85°C and aged. Activated carbon and Hyflo were added to the solution and the mixture was aged again. The suspension was filtered at about 90°C. The filter unit and filter cake were washed several times with benzyl alcohol. The clear filtrate was transferred to another reactor and cooled to about 70°C. Staurosporine B2 suspended in ethanol was added to the solution as a seed crystal. After that, ethanol was added to the suspension, and the suspension was aged and then cooled to about 0°C. The suspension was aged again at about 0°C for at least 2 h. Staurosporine B2 was separated by filtration. The product was washed several times with ethanol.

Embodiment 3

[0096] Example 3 Benzylation of staurosporine B2 to prepare substantially amorphous N-benzoyl-staurosporine

[0097] Add staurosporine B2 with benzoic anhydride, ethanol and water to the reactor. The reaction mixture was heated to about 70°C and aged. The solution was filtered, and the filter unit and filter cake were washed with ethanol several times. The filtrate was transferred to another reactor and cooled to about 60°C. Water was slowly added to the solution. Amorphous N-benzoyl-staurosporine was added to the solution as seed crystals. The suspension was aged, then cooled to 20°C and aged again. N-Benzoyl-staurosporine was isolated by filtration. The wet cake of N-benzoyl-staurosporine was washed several times with absolute ethanol. The wet filter cake was resuspended in ethanol in the filter unit, aged at about 25°C, then cooled to about 0-5°C, and aged again. The processing steps can be repeated multiple times. N-benzoyl-staurosporine was isolated by filtratio...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a new crystalline form II of N-benzoyl-staurosporine; compositions containing the same; processes for the preparation thereof; and the use of crystalline form II of of N-benzoyl-staurosporine in diagnostic methods or therapeutic treatment of warm-blooded animals, especially humans. The invention relates to the amorphous forms of N-benzoyl-staurosporine; compositions containing the same; processes for the preparation thereof; and the use of amorphous N-benzoyl-staurosporine in diagnostic methods or therapeutic treatment of warm-blooded animals, especially humans.

Description

[0001] This application is a divisional application of Chinese patent application 200580037222.X, the filing date of the original application is November 3, 2005, and the title of the invention is "organic compound". [0002] The present invention relates to a new crystal form II of N-benzoyl-staurosporine, a preparation method of N-benzoyl-staurosporine crystal form II, and a method containing N-benzoyl-staurosporine The composition of crystal form II and the use of N-benzoyl-staurosporine crystal form II in the diagnosis method or treatment of warm-blooded animals, especially human. [0003] The present invention relates to amorphous N-benzoyl-staurosporine, a preparation method of amorphous N-benzoyl-staurosporine, and a combination containing amorphous N-benzoyl-staurosporine and the use of amorphous N-benzoyl-staurosporine in the diagnostic method or treatment of warm-blooded animals, especially humans. Background of the invention [0004] The drug N-benzoyl-staurosporin...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07D498/22
Inventor P·赫恩B·科克M·穆兹
Owner NOVARTIS AG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com